Abstract:Objective:To study the clinical value of p53 and neuroendocrine differentiation (NE) markers including chromogranin A (CgA),synaptophysin (Syn),and neuroendocrine granules in prognostic assessment of non-small cell lung cancer (NSCLC). Methods:Sixty-two patients were given platinum-based neoadjuvant chemotherapy for 1-2 cycles before surgery. Expression of CgA, Syn, and p53 in resected NSCLC specimens was determined by immunohistochemistry. NE granules were observed by electron microscope. After 3-year follow-up,survival rate was analyzed by SPSS11.0 software. Results:There was statistically significant correlation between progression-free survival (PFS) and expression of p53 and NE differentiation markers (P<0.05) . Conclusion:NE differentiation combined with p53 expression have clinic values in PFS assessment of NSCLC.

Clinical value of neuroendocrine differentiation markers and p53 in prognostic assessment of non small cell lung cancer